Itaconate identified as a new target for pediatric brain tumors called ependymomas
In a study published in Nature , University of Michigan researchers have found that a specific molecule called itaconate drives the development of ependymomas. Their findings can help future drug development for children with this type of malignant brain tumor. Read more: https://www.michiganmedicine.org/health-lab/itaconate-identified-new-target-pediatric-brain-tumors-called-ependymomas
Feb 10
Children with brain cancer given hope in trial of personalised vaccines across eight Australian hospitals
A world-first trial of a personalised vaccine for children with deadly brain cancers will be rolled out in eight hospitals throughout Australia later this year. Read more: https://www.abc.net.au/news/2026-02-03/brain-cancer-vaccine-trial-for-children/106294532
Feb 6
Parents & Clinicians Diverge on Psychosocial Priorities in Pediatric Oncology
A new national study highlights both common ground and key diverging factors between parents and clinicians on what psychosocial needs matter most for children with cancer. Read more: https://journals.lww.com/oncology-times/fulltext/2026/02000/parents___clinicians_diverge_on_psychosocial.2.aspx
Feb 5
Pan-Canadian research team dedicated to improving the lives of children with cancer and their families
Knowledge Mobilization Group seeks to understand the knowledge mobilization needs of the childhood cancer community from the perspectives of both children and adults. Read more: https://www.mcgill.ca/nursing/article/pan-canadian-research-team-dedicated-improving-lives-children-cancer-and-their-families
Feb 4
FDA Approves Larger Nelarabine Vial for Some Leukemias and Lymphomas
The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric patients with T-ALL and T-LBL. Read more: https://www.curetoday.com/view/fda-approves-larger-nelarabine-vial-for-some-leukemias-and-lymphomas
Feb 3